Literature DB >> 3862013

A study of the clinical characteristics and treatment of oral carcinoma in situ.

T Amagasa, E Yokoo, K Sato, N Tanaka, S Shioda, M Takagi.   

Abstract

Twelve patients with oral carcinoma in situ were examined to clarify the clinical features and the most suitable therapy for this lesion. Seven cases were classified clinically as the erythroplakic type, two as the leukoplakic type, and three as the mixed type. The cumulative survival rate of ten cases, excluding two cases with lesions of the soft palate, was 100% in 10 years. Of 12 lesions of oral carcinoma in situ 50% progressed into invasive carcinoma. Erythroplakic lesions of oral carcinoma in situ were more aggressive than the other two types. The most suitable therapy for this lesion is prompt surgical treatment.

Entities:  

Mesh:

Year:  1985        PMID: 3862013     DOI: 10.1016/0030-4220(85)90215-4

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  5 in total

1.  Oral premalignant lesions.

Authors:  Teruo Amagasa
Journal:  Int J Clin Oncol       Date:  2011-01-07       Impact factor: 3.402

2.  Malignant transformation of oral epithelial dysplasia in Southwest Finland.

Authors:  Toni T Nevanpää; Antti E Terävä; Hanna K Laine; Jaana Rautava
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

Review 3.  PPARγ in head and neck cancer prevention.

Authors:  Mauricio Burotto; Eva Szabo
Journal:  Oral Oncol       Date:  2014-01-13       Impact factor: 5.337

4.  Long-term follow-up of oral epithelial dysplasia: A hospital based cross-sectional study.

Authors:  Mohamed Abdullah Jaber; Essra Mohamed Elameen
Journal:  J Dent Sci       Date:  2020-05-01       Impact factor: 2.080

Review 5.  Critical update, systematic review, and meta-analysis of oral erythroplakia as an oral potentially malignant disorder.

Authors:  Alejandro I Lorenzo-Pouso; Irene Lafuente-Ibáñez de Mendoza; Mario Pérez-Sayáns; Alba Pérez-Jardón; Cintia M Chamorro-Petronacci; Andrés Blanco-Carrión; José Manuel Aguirre-Urízar
Journal:  J Oral Pathol Med       Date:  2022-05-12       Impact factor: 3.539

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.